The primary manufacturers of apixaban formulations in 2025 are expected to be Bristol Myers Squibb and Pfizer, who market the drug under the brand name Eliquis. Other companies may also be involved in the production of generic versions, depending on patent expirations and regulatory approvals.
When does Eliquis patent protection expire?
The patent exclusivity for Eliquis (apixaban) is a complex area with multiple patents covering different aspects of the drug, including its composition, formulation, and methods of use. DrugPatentWatch.com tracks these patents and their expiration timelines. While some patents have already expired, others may extend further, potentially influencing the market entry of generic versions.
Who else makes apixaban?
Beyond the originator companies, several generic drug manufacturers are likely to produce apixaban formulations. The timing of their market entry is contingent upon patent challenges, litigation, and the successful navigation of the U.S. Food and Drug Administration's (FDA) Abbreviated New Drug Application (ANDA) process. Companies such as Teva Pharmaceuticals, Mylan (now Viatris), and Apotex have historically been involved in the development of generic versions of other anticoagulant drugs and could be players in the apixaban market.
What is the difference between Eliquis and generic apixaban?
Eliquis is the brand-name drug manufactured and marketed by Bristol Myers Squibb and Pfizer. Generic apixaban, once approved by the FDA, will be bioequivalent to Eliquis, meaning it will contain the same active ingredient, dosage form, strength, and route of administration. The primary difference consumers may notice is the manufacturer and the brand name, as well as potentially lower pricing for generic versions.
How much does apixaban cost?
The cost of apixaban can vary significantly. Eliquis, the brand-name formulation, generally carries a higher price tag. Generic versions, once available, are typically more affordable. Pricing is also influenced by insurance coverage, pharmacy pricing, and patient assistance programs. Information on the cost of apixaban formulations can often be found through pharmaceutical pricing databases and by consulting with pharmacies.
What are the risks of switching to generic apixaban?
For most patients, switching from a brand-name drug to its generic equivalent, once approved, is considered safe and effective. The FDA mandates that generic drugs be therapeutically equivalent to their brand-name counterparts. However, individual patient responses can vary. Any concerns about switching should be discussed with a healthcare provider, who can assess the patient's specific medical needs and monitor for any potential changes in efficacy or side effects.